SCHOTT Pharma AG & Co KgaA

Net income margin, %

19.1

-6.7

EBITDA margin, %

31.1

5.6

Debt to Equity, %

10.4

15.1

Intangible assets and goodwill, %

2.4

4.7

Revenue CAGR 3Y, %

15.4

12.8

P/E

36.2

32.1

P/BV

7.9

2

P/S

6.3

4.1

EV/S

6.3

3.6

EV/EBITDA

24.7

7.8

Average Analyst recommendation

Hold

Hold

Average upside forecasts, %

1.4

48.9

Forward P/E

33.4

25.5

Dividend Yield, %

0.3

0.8

Forward Dividend Yield, %

0.5

0.2

Expected dividend per share

0.1

0

Dividend Ex Date

2024-03-15